A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease

Inclusion Criteria: * Males and females, 18 years or older * Confirmed enzymatic diagnosis of Gaucher disease * Splenomegaly defined as greater than eight times the expected volume (measured volume divided by estimated volume (0.2% of body weight)\] as determined by MRI volumetric analysis * Female patients of child-bearing potential who agree to use a medically acceptable method of contraception * Thrombocytopenia (defined as platelet counts below the lower limit of normal) and/or anemia (defined by hemoglobin level at least 1 g/dL below normal range according to sex and age). * Patients who have not received ERT in the past or patients whoc have not received ERT in the past 12 months and have a negative anti-glucocerebrosidase antibody test. * Patients who have not received substrate reduction therapy (SRT) in the past 12 months. * Ability to provide a written informed consent. Exclusion Criteria: * Currently taking another experimental drug for any condition * Pregnant or nursing * Presence of HIV and/or, HBsAg and/or hepatitis C infections * Presence of severe neurological signs and symptoms, defined as complete ocular paralysis, overt myoclonus or history of seizures, characteristic of neuronopathic Gaucher disease. * Previous anaphylactoid reaction to Cerezyme® or Ceredase®. * History of allergy to carrots.